The project concerns research and development in new medicinal products targeting diabetes and obesity.
The R&D investments focus on improving the features of specific product lines as well as basic research in Europe. The project would enhance the leading competitive position of an EU knowledge-based, R&D-driven enterprise.
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities making use of existing laboratories, pilot plants, clinical centres, etc. An Environmental Impact Assessment (EIA) by a competent authority according to the EU Directive 97/11 amended by Directive 2003/35 should not be required.
The promoter is a private company, not operating in the Utilities sector and therefore not covered by EU Directives on procurement. Procedures followed are in the best interest of the project and satisfactory to the Bank.
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The data provided on this page is therefore indicative and cannot be considered to represent official EIB policy (see also the Explanatory notes).
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how the EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.